Theravance Biopharma (NASDAQ:TBPH) Price Target Lowered to $21.00 at BTIG Research

Theravance Biopharma (NASDAQ:TBPH) had its price target reduced by investment analysts at BTIG Research from $40.00 to $21.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. BTIG Research’s price target indicates a potential upside of 50.11% from the stock’s previous close.

A number of other analysts have also recently weighed in on TBPH. Weiss Ratings reissued a “hold (c)” rating on shares of Theravance Biopharma in a report on Thursday, January 22nd. HC Wainwright boosted their price objective on Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a research note on Monday. Wall Street Zen downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. Finally, Oppenheimer assumed coverage on shares of Theravance Biopharma in a report on Wednesday, December 3rd. They issued an “outperform” rating and a $27.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $25.40.

Theravance Biopharma Price Performance

Shares of TBPH traded down $4.96 during mid-day trading on Tuesday, reaching $13.99. The company’s stock had a trading volume of 2,578,357 shares, compared to its average volume of 498,993. Theravance Biopharma has a 12-month low of $7.90 and a 12-month high of $21.03. The stock has a market cap of $708.87 million, a PE ratio of 24.59 and a beta of 0.17. The company’s 50 day moving average is $19.35 and its 200 day moving average is $16.87.

Insider Transactions at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 31,067 shares of the firm’s stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $18.75, for a total value of $582,506.25. Following the completion of the sale, the senior vice president owned 277,695 shares in the company, valued at $5,206,781.25. This trade represents a 10.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.90% of the stock is owned by corporate insiders.

Institutional Trading of Theravance Biopharma

Institutional investors have recently modified their holdings of the business. Arrowstreet Capital Limited Partnership acquired a new stake in Theravance Biopharma in the third quarter valued at $10,611,000. Assenagon Asset Management S.A. lifted its position in shares of Theravance Biopharma by 1,629.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 414,715 shares of the biopharmaceutical company’s stock valued at $6,055,000 after acquiring an additional 390,735 shares during the period. Pacer Advisors Inc. acquired a new stake in shares of Theravance Biopharma in the 4th quarter worth approximately $6,342,000. Hillsdale Investment Management Inc. purchased a new position in Theravance Biopharma in the 3rd quarter valued at approximately $4,536,000. Finally, Janus Henderson Group PLC raised its holdings in Theravance Biopharma by 214.8% during the fourth quarter. Janus Henderson Group PLC now owns 400,496 shares of the biopharmaceutical company’s stock worth $7,493,000 after purchasing an additional 273,288 shares during the last quarter. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

Theravance Biopharma News Summary

Here are the key news stories impacting Theravance Biopharma this week:

• Positive Sentiment: Company announced a deep cost reduction and restructuring expected to cut the cost base by ~60% (about $70M) and generate roughly $60–$70M of annualized cash flow, which should materially extend runway. Theravance press release
• Positive Sentiment: Balance sheet and near-term cash outlook remain supportive: $326.5M cash at Q4 2025 and roughly $400M expected at end‑Q1 2026 (including milestones); management said it’s highly confident of a $100M 2026 TRELEGY milestone. Theravance press release
• Neutral Sentiment: Board has accelerated a strategic review and engaged advisors (Lazard) to evaluate alternatives — including a possible sale — which creates execution uncertainty but could unlock value if a transaction or focused restructuring materializes. Reuters: strategic review
• Negative Sentiment: Phase 3 CYPRESS missed its primary endpoint (OHSA composite) for ampreloxetine in symptomatic neurogenic orthostatic hypotension (nOH) due to multiple system atrophy — this removes the company’s lead late‑stage asset and is the proximate cause of the sharp share decline. Theravance press release
• Negative Sentiment: Market reaction: shares plunged on the trial news, trading was briefly halted, and put buying surged (roughly a ~983% jump in put volume versus typical levels), signaling elevated downside hedging/speculation and continued volatility near term.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.